168 related articles for article (PubMed ID: 35740636)
61. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
Lolli C; Basso U; Derosa L; Scarpi E; Sava T; Santoni M; Crabb SJ; Massari F; Aieta M; Conteduca V; Maruzzo M; La Russa F; Wheater M; Berardi R; Galli L; De Giorgi U
Oncotarget; 2016 Aug; 7(34):54564-54571. PubMed ID: 27409344
[TBL] [Abstract][Full Text] [Related]
62. A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma.
Kato R; Kojima T; Sazuka T; Yamamoto H; Fukuda S; Yamana K; Sugino Y; Hamamoto S; Nakaigawa N; Kabu K; Murakami H; Obara W
Anticancer Res; 2021 Dec; 41(12):6199-6209. PubMed ID: 34848474
[TBL] [Abstract][Full Text] [Related]
63. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract][Full Text] [Related]
64. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
[TBL] [Abstract][Full Text] [Related]
65. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares L; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Sakai H; Lingua A; Salman P; Souquet PJ; De Marchi P; Martin C; Pérol M; Scherpereel A; Lu S; John T; Carbone DP; Meadows-Shropshire S; Agrawal S; Oukessou A; Yan J; Reck M
Lancet Oncol; 2021 Feb; 22(2):198-211. PubMed ID: 33476593
[TBL] [Abstract][Full Text] [Related]
66. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study).
Rebuzzi SE; Signori A; Banna GL; Maruzzo M; De Giorgi U; Pedrazzoli P; Sbrana A; Zucali PA; Masini C; Naglieri E; Procopio G; Merler S; Tomasello L; Fratino L; Baldessari C; Ricotta R; Panni S; Mollica V; Sorarù M; Santoni M; Cortellini A; Prati V; Soto Parra HJ; Stellato M; Atzori F; Pignata S; Messina C; Messina M; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Roviello G; Pierantoni F; Casadei C; Bersanelli M; Chiellino S; Paolieri F; Perrino M; Brunelli M; Iacovelli R; Porta C; Buti S; Fornarini G
Ther Adv Med Oncol; 2021; 13():17588359211019642. PubMed ID: 34046089
[TBL] [Abstract][Full Text] [Related]
67. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
[TBL] [Abstract][Full Text] [Related]
68. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S; Scherpereel A; Cornelissen R; Oulkhouir Y; Greillier L; Kaplan MA; Talbot T; Monnet I; Hiret S; Baas P; Nowak AK; Fujimoto N; Tsao AS; Mansfield AS; Popat S; Zhang X; Hu N; Balli D; Spires T; Zalcman G
Ann Oncol; 2022 May; 33(5):488-499. PubMed ID: 35124183
[TBL] [Abstract][Full Text] [Related]
69. Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy.
Rajwa P; Schuettfort VM; Quhal F; Mori K; Katayama S; Laukhtina E; Pradere B; Motlagh RS; Mostafaei H; Grossmann NC; Aulitzky A; Paradysz A; Karakiewicz PI; Fajkovic H; Zimmermann K; Heidenreich A; Gontero P; Shariat SF
World J Urol; 2021 Oct; 39(10):3771-3779. PubMed ID: 33997919
[TBL] [Abstract][Full Text] [Related]
70. Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.
Brown LC; Desai K; Wei W; Kinsey EN; Kao C; George DJ; Rini BI; Ornstein MC; Zhang T
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518292
[TBL] [Abstract][Full Text] [Related]
71. Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States.
van Boemmel-Wegmann S; Brown JD; Diaby V; Huo J; Silver N; Park H
JCO Oncol Pract; 2022 Jan; 18(1):e163-e174. PubMed ID: 34228489
[TBL] [Abstract][Full Text] [Related]
72. [Risk Classification and Nivolumab plus Ipilimumab Combination Therapy for Treatment of Renal Cell Carcinoma].
Oya M; Tajima Y; Kabu K
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1397-1404. PubMed ID: 31530779
[TBL] [Abstract][Full Text] [Related]
73. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
[TBL] [Abstract][Full Text] [Related]
74. Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma.
Iwaki T; Niimi A; Kano M; Kurokawa Y; Yoshizaki U; Nozaki K; Nomiya A; Miyazaki H; Kume H
IJU Case Rep; 2021 Jan; 4(1):32-35. PubMed ID: 33426493
[TBL] [Abstract][Full Text] [Related]
75. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution.
Vila CM; Moreno FA; Estébanez MM; Ares GR; Villacampa G; Dashti P; Oberoi HS; Martin-Huertas R; Jares P; Alos L; Teixido C; Rull R; Sanchez M; Malvehy J; Carcelero E; Valduvieco I; Fernandez AA
Clin Transl Oncol; 2022 Feb; 24(2):319-330. PubMed ID: 34420138
[TBL] [Abstract][Full Text] [Related]
76. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
Amaral T; Kiecker F; Schaefer S; Stege H; Kaehler K; Terheyden P; Gesierich A; Gutzmer R; Haferkamp S; Uttikal J; Berking C; Rafei-Shamsabadi D; Reinhardt L; Meier F; Karoglan A; Posch C; Gambichler T; Pfoehler C; Thoms K; Tietze J; Debus D; Herbst R; Emmert S; Loquai C; Hassel JC; Meiss F; Tueting T; Heinrich V; Eigentler T; Garbe C; Zimmer L;
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221017
[TBL] [Abstract][Full Text] [Related]
77. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL
J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203
[TBL] [Abstract][Full Text] [Related]
78. Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy.
Grossmann NC; Schuettfort VM; Pradere B; Rajwa P; Quhal F; Mostafaei H; Laukhtina E; Mori K; Motlagh RS; Aydh A; Katayama S; Moschini M; Fankhauser CD; Hermanns T; Abufaraj M; Mun DH; Zimmermann K; Fajkovic H; Haydter M; Shariat SF
Urol Oncol; 2022 Mar; 40(3):106.e11-106.e19. PubMed ID: 34810077
[TBL] [Abstract][Full Text] [Related]
79. Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy.
Carril-Ajuria L; Lora D; Carretero-González A; Martín-Soberón M; Rioja-Viera P; Castellano D; de Velasco G
Clin Genitourin Cancer; 2021 Apr; 19(2):95-102. PubMed ID: 33189597
[TBL] [Abstract][Full Text] [Related]
80. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.
Wu B; Zhang Q; Sun J
J Immunother Cancer; 2018 Nov; 6(1):124. PubMed ID: 30458884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
